ResMed chairman & CEO Michael Farrell sells $968k in stock
ResMed Inc.'s Chairman and CEO, Michael J. Farrell, sold 4,991 shares of the company's common stock for approximately $968,064 on June 8, 2026, under a Rule 10b5-1 plan. On the same day, Mr. Farrell also acquired 4,991 shares through option exercise for $730,382. These transactions provide a comprehensive view of ResMed’s current financial and strategic position, alongside recent mixed Q3 2026 earnings, the acquisition of Noctrix Health, and varied analyst ratings.
ResMed chairman & CEO Michael Farrell sells $968k in stock
Michael J. Farrell, Chairman and CEO of ResMed Inc., sold 4,991 shares of the company's common stock for $968,064 on June 8, 2026, after exercising options for the same number of shares. The transactions were conducted under a Rule 10b5-1 plan. ResMed recently reported mixed Q3 2026 earnings, beating EPS forecasts but slightly missing revenue, and acquired Noctrix Health for $340 million, leading to varied analyst reactions.
Resmed Insider Sold Shares Worth $968,064, According to a Recent SEC Filing
An insider at ResMed (RMD) recently sold shares valued at $968,064, as disclosed in a filing with the U.S. Securities and Exchange Commission (SEC). This transaction occurred on June 9, 2026. ResMed specializes in medical devices and software for respiratory disorders, particularly sleep-related issues.
ResMed (NYSE: RMD) CEO sells 4,991 shares after option exercise
ResMed's Chairman and CEO, Michael J. Farrell, exercised options to acquire 4,991 shares of company stock at $146.34 per share and subsequently sold them for a weighted average price of $193.962. These transactions, totaling $968,064, were conducted on June 8, 2026, under a pre-arranged Rule 10b5-1 plan. Following the sale, Farrell directly holds 466,256 ResMed shares, with additional shares held indirectly and stock options remaining outstanding.
Is This the Right Time to Retain Resmed Stock in Your Portfolio?
Resmed (RMD) is positioned for growth due to its expanding Residential Care Software segment, driven by strategic acquisitions, and continuous innovation in its mask portfolio. While the company demonstrates strong financial health, it faces challenges from macroeconomic pressures and intense competition. Investors should consider these factors when evaluating whether to retain Resmed stock.
ResMed Inc. stock falls Monday, underperforms market
ResMed Inc. (RMD) shares fell by 1.48% on Monday, closing at $193.14. This performance led to an underperformance compared to the broader market, as the S&P 500 Index rose by 0.30% and the Dow Jones Industrial Average declined by 0.16%. The drop ended a three-day winning streak for the company's stock.
J&J glows with $1B buyout of Firefly and its degrader platform tech
Johnson & Johnson has acquired Firefly Bio for $1 billion to gain access to its degrader antibody conjugate (DAC) platform technology. This acquisition is part of J&J's strategy to develop new treatments for KRAS-driven tumors, which are traditionally difficult to treat. Firefly Bio's platform combines concepts from antibody drug conjugates and protein degraders to selectively target tumor cells while sparing healthy tissue.
Michael Farrell sells 4,991 RMD shares (NYSE: RMD) via option exercise
Michael Farrell has filed a Form 144 to sell 4,991 shares of ResMed Inc. (NYSE: RMD) common stock through a stock option exercise on June 8, 2026. This filing also discloses three previous monthly dispositions of 4,991 shares each in March, April, and May 2026, with recorded cash proceeds. The filing is described as a routine insider disposition and does not indicate any unusual market or legal events.
PBU The Pension Fund of Early Childhood & Youth Educators Makes New $7.93 Million Investment in ResMed Inc. $RMD
PBU The Pension Fund of Early Childhood & Youth Educators has made a significant new investment of $7.93 million in ResMed Inc., purchasing 32,933 shares in the fourth quarter. This comes as ResMed reported strong quarterly results, exceeding EPS estimates and showing a 10.8% year-over-year revenue increase. The company also declared a $0.60 quarterly dividend, and analysts maintain a "Moderate Buy" rating with a consensus target price of $286.18.
Goldman Sachs Group Inc. Has $235.83 Million Stock Position in ResMed Inc. $RMD
Goldman Sachs Group Inc. increased its stake in ResMed Inc. by 13.7% in the fourth quarter, bringing its total holdings to 979,087 shares valued at approximately $235.8 million. ResMed reported strong quarterly earnings of $2.86 per share, beating analyst estimates, with revenue up 10.8% year over year. The company declared a quarterly dividend of $0.60 per share and maintains a "Moderate Buy" consensus rating from analysts with an average price target of $286.18.
Cibc World Market Inc. Sells 8,768 Shares of ResMed Inc. $RMD
Cibc World Market Inc. reduced its stake in ResMed Inc. by 20.9% in the fourth quarter, selling 8,768 shares and retaining 33,170 shares valued at approximately $7.99 million. Despite this sale, ResMed has shown strong financial performance, beating earnings and revenue estimates with EPS of $2.86 and revenue of $1.43 billion, an increase of 10.8% year-over-year. Analysts maintain a "Moderate Buy" consensus rating with a target price of $286.18, reflecting continued positive sentiment for the medical equipment provider.
BI Asset Management Fondsmaeglerselskab A S Reduces Stock Position in ResMed Inc. $RMD
BI Asset Management Fondsmaeglerselskab A S has reduced its stake in ResMed Inc. by 14.6% in the fourth quarter, selling 10,686 shares and holding 62,362 shares valued at $15.02 million. This comes as other institutional investors have either increased or initiated positions in the medical equipment provider. ResMed recently reported strong quarterly earnings and announced a quarterly dividend, while company insiders have also sold shares.
ResMed (RMD) Valuation Check After Q3 FY2026 Results And Sleep Apnea Demand Update
ResMed (RMD) is under investor scrutiny following its Q3 FY2026 results, which showed revenue growth and solid cash flow, despite the stock being down over the past year. While one valuation model suggests it's 6.5% overvalued at $194.32, another perspective focuses on its P/E ratio of 18.5x, which is below the peer average, indicating potential for movement. The article highlights both the opportunities presented by recent results and acquisitions, as well as risks such as the impact of GLP-1 therapies on CPAP demand.
CIBC Asset Management Inc Boosts Holdings in ResMed Inc. $RMD
CIBC Asset Management Inc increased its stake in ResMed Inc. by 67.4% during the fourth quarter, bringing its total holdings to 34,588 shares valued at $8.33 million. Other institutional investors also significantly adjusted their positions in RMD, while analysts have given the stock a "Moderate Buy" rating with a consensus target price of $286.18. ResMed recorded strong Q4 earnings, beating analyst expectations, and announced a quarterly dividend.
ResMed (RMD) Acquires Noctrix Health to Expand Sleep Disorder Portfolio
ResMed (RMD) has completed the acquisition of Noctrix Health, a medical device company specializing in non-pharmacologic wearable therapeutics. This acquisition expands ResMed's clinical sleep health portfolio to include treatments for Restless Legs Syndrome/RLS with Noctrix Health's Nidra Tonic Motor Activation/TOMAC Therapy. The move aligns with ResMed's strategy to advance home-based sleep and respiratory care and integrates Noctrix Health as a wholly-owned subsidiary.
ResMed (RMD) Acquires Noctrix Health to Expand Sleep Disorder Portfolio
ResMed (RMD) has acquired medical device company Noctrix Health, expanding its clinical sleep health portfolio to include treatments for Restless Legs Syndrome using Nidra Tonic Motor Activation (TOMAC) Therapy. This FDA-classified non-invasive device is designed for adults with moderate-to-severe RLS who haven't found relief from traditional drugs. Noctrix Health will operate as a wholly-owned subsidiary, aligning with ResMed's strategy to advance home-based sleep and respiratory care.
ResMed Inc. (RMD) Presents at 46th Annual William Blair Growth Stock Conference - Slideshow
ResMed Inc. (RMD) presented at the 46th Annual William Blair Growth Stock Conference, sharing a slideshow related to the event. The presentation was published on June 5, 2026, and is available for viewing. SA Transcripts is responsible for covering the event and related developments.
ResMed Inc. $RMD Shares Sold by Marietta Investment Partners LLC
Marietta Investment Partners LLC significantly reduced its stake in ResMed Inc. ($RMD) by 87.7% in the fourth quarter, selling 8,648 shares. This sale aligns with broader insider selling trends, as Director Peter C. Farrell and CEO Michael J. Farrell also sold shares recently, totaling 16,973 shares worth $3.87 million over the past 90 days. Despite these sales, ResMed reported strong quarterly results, beating EPS estimates and announcing a quarterly dividend.
A Look at ResMed Inc (RMD) After 4.2% Gain -- GF Value $271.26 v
ResMed Inc. (RMD) shares gained 4.2% today, trading at $194.32, which is 28.4% below its GF Value of $271.26, indicating it is "Modestly Undervalued." Despite a strong GF Score of 90/100, driven by high profitability and growth, the company has seen significant insider selling totaling $4.6 million over the past three months, with no buying activity. This suggests potential caution among insiders despite the stock's undervaluation and strong fundamentals.
ResMed Inc. stock rises Thursday, outperforms market
ResMed Inc. (RMD) stock increased by 4.22% on Thursday, closing at $194.32. This performance outperformed the broader market, as both the S&P 500 Index and the Dow Jones Industrial Average also saw gains. This marks the second consecutive day of increases for ResMed's stock.
BofA Securities Maintains ResMed(RMD.US) With Buy Rating, Raises Target Price to $320
BofA Securities has reiterated its Buy rating on ResMed (RMD.US) and increased its price target to $320. This indicates a positive outlook on the company's future performance by the investment bank.
ResMed completes $340m Noctrix Health acquisition
ResMed has acquired Noctrix Health for $340 million, marking the first exit for Angelini Ventures. Noctrix Health's lead product, Nidra, is a non-invasive therapy for restless leg syndrome that uses wearable cuffs to deliver electrical pulses to the peroneal nerves, which was FDA-cleared in 2023. This acquisition will integrate Nidra into ResMed's existing sleep medicine offerings, expanding treatment options for patients with RLS.
New 4-hour test links charge and size in bispecific antibodies and biosimilars
Bio-Techne and Refeyn have launched an integrated workflow that significantly reduces the time and sample volume needed to characterize bispecific antibodies and biosimilars. This new four-hour process combines MauriceFlex™ icIEF fractionation with TwoMP mass photometry, allowing direct correlation of charge variants with size and aggregation using nanogram-level samples. The innovation aims to lower development risk, accelerate biosimilar manufacturing, and provide critical insights not achievable with traditional standalone methods.
Is ResMed a Better Buy Than Medtronic?
This article compares ResMed (RMD) and Medtronic (MDT) stocks, arguing that ResMed is a better investment due to superior revenue growth, higher profitability, and a relatively lower valuation. It presents detailed financial metrics and historical market performance data to support the claim, while also cautioning about investment risks and suggesting a portfolio approach.
ResMed (NYSE: RMD) counsel surrenders shares for RSU tax withholding
ResMed's Global General Counsel, Michael J. Rider, reported a tax-related disposition of 268.742 shares of common stock. These shares, valued at $190.57 each, were surrendered on June 1, 2026, to cover tax withholding obligations arising from the vesting of Restricted Stock Units granted in 2023. This transaction was a tax mechanism and not an open-market sale, leaving Rider with 9,488 direct shares, including shares from an employee stock purchase plan.
ResMed Inc. stock rises Wednesday, outperforms market
ResMed Inc. (RMD) shares rose 1.99% on Wednesday to $186.46, bucking the broader market trend as the S&P 500 and Dow Jones Industrial Average both fell. This increase ended an eight-day losing streak for ResMed.
Westpac Banking Corp Has $5.43 Million Position in ResMed Inc. $RMD
Westpac Banking Corp significantly increased its stake in ResMed Inc. by 1,762.4% in the fourth quarter, bringing its total holdings to 22,535 shares valued at $5.43 million. This increase follows ResMed's strong quarterly results, which saw earnings of $2.86 per share and revenue of $1.43 billion, both exceeding analyst expectations. The company also declared a quarterly dividend of $0.60 per share, reinforcing a generally positive outlook from analysts who rate the stock a "Moderate Buy."
Resmed tackles restless legs syndrome with Noctrix Health takeover
Resmed Inc. has acquired Noctrix Health for US$340 million, expanding its sleep technology focus to include restless legs syndrome (RLS) treatment. This acquisition brings Noctrix's FDA-authorized Nidra device, a wearable Tonic Motor Activation therapy, into Resmed's portfolio. The move allows Resmed to compete in the RLS market, previously dominated by pharmaceutical companies, and broaden its presence beyond traditional sleep apnea and respiratory care.
Norges Bank Makes New Investment in ResMed Inc. $RMD
Norges Bank has initiated a new stake in ResMed Inc. (NYSE:RMD), acquiring over 1 million shares valued at approximately $249 million. This investment makes Norges Bank a significant shareholder with about 0.71% ownership. The investment comes as ResMed recently reported strong quarterly results, exceeding revenue and EPS estimates, and analysts maintain a "Moderate Buy" rating with a target price of $286.18.
ResMed Inc. $RMD Shares Acquired by Bank of New York Mellon Corp
Bank of New York Mellon Corp significantly increased its stake in ResMed Inc. (NYSE:RMD) by 7.4% in the fourth quarter, acquiring an additional 337,738 shares, bringing its total to 4.89 million shares valued at approximately $1.18 billion. ResMed reported strong quarterly results, with EPS of $2.86 exceeding estimates and revenue up 10.8% year-over-year. The company declared a quarterly dividend of $0.60 per share, while analysts maintain a "Moderate Buy" rating with a consensus price target of $286.18.
Q1 2026 Life Sciences Earnings Review: PacBio vs. West Pharmaceutical Performance - News and Statistics
A Q1 2026 earnings review for life sciences tools and services stocks shows mixed results, with PacBio underperforming due to flat revenues and a significant miss on analyst expectations. Conversely, West Pharmaceutical Services delivered a strong quarter, exceeding revenue expectations with a 21% year-on-year increase. The sector overall saw satisfactory performance, with revenues beating consensus by 1.2% and share prices rising by an average of 10.2%.
RMD Financials: Revenue Breakdown, Margins & Competitor Comparison
This article provides a financial analysis of Resmed Inc (RMD), detailing its revenue breakdown, profitability margins, and a comparison with competitors like GEHC and DXCM. RMD's primary revenue driver is its Devices segment, accounting for 51.4% of total sales. The company exhibits strong profitability with a gross margin of 61.46%, an operating margin of 35.33%, and a net margin of 27.86%.
ResMed Inc. stock falls Tuesday, underperforms market
ResMed Inc. (RMD) shares fell by 1.94% on Tuesday, closing at $182.82, marking its eighth consecutive day of losses. This occurred despite a generally positive trading session for the broader market, with both the S&P 500 Index and the Dow Jones Industrial Average seeing gains.
Could Cash Machine ResMed Stock Be Your Next Buy?
This article from Trefis poses the question of whether ResMed stock, described as a "cash machine," could be a good investment. The content is primarily a navigation and legal disclaimer section for the Trefis website, with no actual editorial content discussing ResMed. It appears to be a stub or an incomplete article.
Resmed completes $340M Noctrix takeover
Resmed has completed its $340 million acquisition of Noctrix Health, adding a noninvasive device for restless legs syndrome (RLS) to its product portfolio. The device, Nidra, received FDA authorization in 2023 and is expected to benefit from Resmed's existing connections with physicians and home medical equipment providers. Resmed believes this acquisition will allow them to scale Nidra sales faster and address a significant unmet need for RLS treatment, as current drug therapies have many side effects.
Stryker Stock at Support Zone – Bargain or Trap?
Stryker (SYK) stock is currently trading in a support zone from which it has historically bounced, generating an average peak return of 19.1%. Despite a recent Q1 miss due to a cyberattack, management has reaffirmed strong 2026 guidance, and analysts maintain a "Buy" consensus. The company benefits from industry tailwinds and strategic acquisitions, appearing undervalued near its current support levels.
ResMed Stock Delivers Strong Cash Yield – Upside Ahead?
ResMed (RMD) is presented as a potentially strong investment due to its high free cash flow yield of 6.4%, robust operating margins, and revenue growth, despite being currently undervalued compared to its past performance. The article highlights RMD's solid fundamentals and suggests that the company is well-positioned to either reinvest cash for growth or return it to shareholders. It also places RMD in the context of a diversified portfolio strategy, noting the risks of single-stock investments and suggesting alternative high-cash-yield stocks.
ResMed Completes Acquisition of Noctrix Health
ResMed has announced the completion of its acquisition of Noctrix Health, a commercial-stage medical device company focused on treating symptomatic restless legs syndrome (RLS). This acquisition expands ResMed's portfolio beyond its core sleep apnea and respiratory care solutions into a new adjacent therapeutic area. Noctrix Health's primary product is the NTX100, which uses non-pharmacological neuromodulation to alleviate RLS symptoms.
Resmed Closes Acquisition of Noctrix Health
ResMed announced it has completed its acquisition of Noctrix Health, a private medical device company that developed a neuromodulation therapy for Obstructive Sleep Apnea (OSA). The acquisition aims to expand ResMed's portfolio of solutions for sleep-disordered breathing. Financial terms of the deal were not disclosed.
Resmed completes $340M acquisition of Noctrix Health
Resmed has finalized its $340 million acquisition of Noctrix Health, bringing a new treatment for drug-refractory Restless Legs Syndrome (RLS) into its clinical sleep health portfolio. Noctrix Health's Nidra Tonic Motor Activation (TOMAC) therapy, which is FDA-cleared, uses non-invasive electrical stimulation to reduce RLS symptoms and improve sleep quality. This acquisition is expected to scale innovation, expand patient access, and accelerate the impact of Noctrix's technology by integrating it into Resmed’s connected devices and digital health solutions.
Resmed Completes Acquisition of Noctrix Health, Expanding Clinical Sleep Health Portfolio
Resmed has completed its acquisition of Noctrix Health, a medical device company specializing in wearable therapeutics for chronic neurological disorders. This acquisition expands Resmed's clinical sleep health portfolio to include Nidra® Tonic Motor Activation (TOMAC) Therapy, an FDA-classified non-pharmacologic treatment for moderate-to-severe Restless Legs Syndrome (RLS). The integration aims to scale Noctrix's innovation, improve patient access, and enhance treatment for RLS through Resmed's connected devices and digital health solutions.
Wearable restless legs therapy offers drug-free sleep help for adults
Resmed has completed its acquisition of Noctrix Health, adding Noctrix's FDA-classified Nidra TOMAC Therapy to its clinical sleep health portfolio. This non-invasive, non-pharmacologic treatment addresses moderate-to-severe Restless Legs Syndrome (RLS) and is backed by 10 peer-reviewed publications and AASM clinical practice guidelines. The acquisition supports Resmed's 2030 strategy by expanding into RLS treatment, the third most prevalent sleep disorder.
ResMed Inc. stock falls Monday, underperforms market
ResMed Inc. (RMD) stock decreased by 2.17% on Monday, closing at $186.44. This performance underperformed the broader market, as the S&P 500 Index rose by 0.26% and the Dow Jones Industrial Average gained 0.09%. This marks the seventh consecutive day of losses for ResMed Inc. shares.
1 New 5-Star Stock This Week
Morningstar identified one new 5-star stock for the week ended May 29: ResMed (RMD). The medical supplies company saw its rating change from 4 to 5 stars after its stock price fell 8.40% over the past week, making it undervalued by 34% compared to its fair value estimate of $290. The overall US stock market remains slightly undervalued, with 41% of Morningstar-covered stocks considered undervalued.
ResMed: Transferring Coverage of Global Leader in Respiratory Care Devices
Morningstar is transferring coverage of ResMed Inc., a global leader in respiratory care devices. The article highlights ResMed's strategy of using "smart devices" and Big Data to strengthen its position in the obstructive sleep apnea (OSA) market. This approach aims to improve patient compliance, support reimbursement rates, and gather clinical data demonstrating the benefits of OSA treatment.
Can Inspire Medical Systems (INSP) Convert Revenue Beats Into Sustainable Earnings Strength?
Inspire Medical Systems (INSP) recently reported Q1 results with revenue up 1.6% year-on-year, beating analyst expectations, but missed full-year EPS guidance. The company's investment narrative now focuses on execution for Inspire V adoption and reimbursement clarity, amidst revised lower revenue and EPS guidance for 2026 due to cost inflation and reimbursement pressures. While the positive revenue suggests potential, the softer earnings outlook and ongoing uncertainties could prompt analysts to reassess their growth assumptions.
ResMed And Oura Link Consumer Sleep Data To Clinical Care Pathways
ResMed and Oura have partnered to connect consumer sleep data with clinical care pathways, aiming to broaden access to sleep care and expand their digital health presence. This collaboration is intended to direct Oura users with potential sleep issues to ResMed's resources and could influence ResMed's future digital sleep care product development. Investors will be observing how this partnership impacts user adoption, product integration, and the conversion of wellness interest into clinical engagement amidst ResMed's challenging stock performance.
Bruni J V & Co. Co. Has $22.89 Million Stock Position in Intel Corporation $INTC
Bruni J V & Co. Co. maintains a significant stake in Intel Corporation, holding 620,267 shares valued at $22.89 million, despite a slight 2.1% reduction in the fourth quarter. This makes Intel a substantial 2.2% of their portfolio. The article also highlights Intel's stronger-than-expected quarterly earnings, positive news regarding new product launches and investments in semiconductor manufacturing, and mixed analyst sentiment with an overall "Hold" rating.
United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund Purchases 7,020 Shares of ResMed Inc. $RMD
United Super Pty Ltd, acting as Trustee for the Construction & Building Unions Superannuation Fund, significantly increased its stake in ResMed Inc. by purchasing an additional 7,020 shares in the fourth quarter, bringing its total holdings to 10,420 shares valued at $2.51 million. This increase in institutional ownership comes amidst continued insider selling, with company executives selling shares worth millions in the last 90 days. ResMed recently reported strong quarterly earnings, surpassing analyst expectations, and announced a quarterly dividend of $0.60 per share, while analysts maintain a "Moderate Buy" consensus rating for the stock.
Intech Investment Management LLC Boosts Stock Position in ResMed Inc. $RMD
Intech Investment Management LLC significantly increased its stake in ResMed Inc. (NYSE:RMD) by 116.4% in the fourth quarter, now holding 67,729 shares valued at $16.3 million. This increase aligns with positive financial results for ResMed, which exceeded quarterly earnings estimates and declared a $0.60 per share dividend. Despite insider selling, the company maintains a "Moderate Buy" analyst consensus with a target price of $286.18.
